<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00046995</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000257228</org_study_id>
    <secondary_id>GRECCR-03</secondary_id>
    <secondary_id>EU-20201</secondary_id>
    <nct_id>NCT00046995</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Colon Cancer</brief_title>
  <official_title>5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Regional d'Etudes du Cancer Colorectal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. It is not yet known which schedule of chemotherapy is most&#xD;
      effective in treating colon cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare different schedules of chemotherapy using&#xD;
      carboplatin with fluorouracil and leucovorin in treating patients who have stage IIB or stage&#xD;
      III colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the disease-free survival of patients with completely resected stage IIB or III&#xD;
           colon cancer treated with adjuvant chronomodulated vs standard schedule fluorouracil and&#xD;
           leucovorin calcium with or without carboplatin.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Determine the dose intensities of fluorouracil and carboplatin in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center and disease stage (IIB vs III). Patients are randomized to 1 of 4&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I (standard schedule): Patients receive fluorouracil (5-FU) IV continuously and&#xD;
           leucovorin calcium (CF) IV on days 1 and 2.&#xD;
&#xD;
        -  Arm II (standard + carboplatin schedule): Patients receive 5-FU and CF as in arm I plus&#xD;
           carboplatin IV on day 1.&#xD;
&#xD;
        -  Arm III (chronomodulated schedule): Patients receive 5-FU IV continuously and CF IV&#xD;
           continuously on days 1-4.&#xD;
&#xD;
        -  Arm IV (chronomodulated + carboplatin schedule): Patients receive 5-FU and CF as in arm&#xD;
           III plus carboplatin IV continuously on days 1-4.&#xD;
&#xD;
      Quality of life is assessed.&#xD;
&#xD;
      Treatment in all arms repeats every 14 days for up to 9 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 660-800 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon&#xD;
&#xD;
               -  Stage IIB or III (Dukes stage B2 or C)&#xD;
&#xD;
               -  Complete curative resection performed within the past 7 weeks (negative margins)&#xD;
&#xD;
               -  No local or regional relapsed disease&#xD;
&#xD;
          -  Tumor more than 15 cm above the anal margin&#xD;
&#xD;
          -  Carcinoembryonic antigen less than 5 ng/mL (after surgery)&#xD;
&#xD;
          -  No rectal cancer&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count at least 2,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT no greater than 5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No serious coronary disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent infectious disease&#xD;
&#xD;
          -  No other malignancy except adequately treated basal cell skin cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy (before or after surgery)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian N.J. Focan, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique Saint-Joseph</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Hutois</name>
      <address>
        <city>Huy</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Joseph</name>
      <address>
        <city>Liege</city>
        <zip>B 4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>stage IIB colon cancer</keyword>
  <keyword>stage IIIA colon cancer</keyword>
  <keyword>stage IIIB colon cancer</keyword>
  <keyword>stage IIIC colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

